[Level of Helicobacter pylori infection of the gastric mucosa in the optimization of a daily dose of antihelicobacter drugs].
The efficiency of antihelicobacter therapy was evaluated in 36 and 22 patients from experimental and control groups, respectively. In the control group, antihelicobacter agents were given in usual doses in the control group and in the experimental one; they were used in doses depending on the level of Helicobacter pylori (HP) infection of the gastric mucosa (GM). The findings showed that the efficiency of antihelicobacter therapy was much higher in the group of patients taking antihelicobacter agents in a daily dose depending on the level of GM HP infection.
Orziev
Z M
ZM
Nurbaev
F E
FE
Rakhimova
G Sh
GSh
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D009853:Omeprazole / Q000008:administration & dosage; D009942:Organometallic Compounds / Q000008:administration & dosage; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D008795:Metronidazole; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole